Androgen deficiency in women: Indication and risks of testosterone or DHEA treatment;Déficit en androgènes chez la femme: Indications et risques d'un traitement par la testostérone ou la DHEA

Revue Medicale Suisse

Volumn 3, Issue 104, 2007, Pages 792-798

  Martin Du Pan, R ^a  

^a NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE; TESTOSTERONE;

ADDISON DISEASE; ANDROGEN DEFICIENCY; BREAST CANCER; CANCER RISK; HUMAN; LIBIDO DISORDER; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; TREATMENT INDICATION; WELLBEING;

ADRENAL INSUFFICIENCY; ANDROGENS; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE;

EID: 34247170818     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Bachmann G, Brancroft J, Brauenstein G. Female androgen insufficiency: The Princeton consensus statement on definition, classification and assessment. Fertil Steril 2002;77:660-5.
2. Shifren JL, Davis SR, Andersten LT. The role of testosterone therapy in postmenopausal women: Position statement of the North american menopause society. Menopause 2005;5:497-511.
3. Wierman ME, Basson R, Davis SR. Androgen therapy in women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:3697-710.
4. Arte W. Androgen therapy in women. Eur J Endocrinol 2006;154;1-11.
5. Davidson SL, Bell R, Donath S. Androgen levels in adult females: Changes with age, menopause and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53.
6. Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 2005;90:1428-33.
7. Dolan S, Willike S, Aliabadi N. Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: A randomised placebo-controlled study. Arch Intern Med 2004;164:897-904.
8. Ktaridou SN, Calis KA, Mazer NA. A pilot study of an investigational testosterone transdermal patch system in young women with spontaneous premature ovarian failure. J Clin Endocrinol Metab 2005;90;6549-52.
9. Davis SR, Davison SL, Donath S. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-6.
10. Santoro N, Torrens J, Crawford S. Correlates of circulating androgens in mid-life women: The study of women's health across the nation. J Clin Endocrinol Metab 2005;90:4836-45.
11. Basson R. Sexual desire and arousal disorders in women. N Engl J Med 2005;254:1497-506.
12. Bancroft J, Loftus J, Long JS. Distress about sex: A national survey of women in heterosexual relationships. Arc Sex Behav 2003;32:193-208.
13. Ponholzer A, Roehlich M, Raez U. Female sexual dysfunction in a healthy austrian cohort: Prevalence and risk factors. Eur Urol 2005;47:366-75.
14. Geiss IM, Umek WH, Dungl A. Prevalence of female sexual dysfunction in gynaecologic and urogynecologic patients according to the international consensus classification. Urology 2003;62;514-8.
15. Dennerstein L, Lehert P, Burger H. The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition. Fertil Steril 2005;84:175-80.
16. Nathorst-Boos J, Wiklund I, Mattsson LA, et al. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obst Gynecol Scand 1993;72:656-60.
17. Davis SR, Goldstat R, Papalia MA. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: A randomised, placebo-controlled trial. Menopause 2006;13:37-45.
18. Nathorst-Boos J, Von Schoulz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 1992;34:97-101.
19. Aszs A, Brannstorm M, Beregquist C. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005;83:1021-8.
20. Singh AB, Lee ML, Sinha-Hikim I. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J Clin Endocrinol Metab 2006;91:136-44.
21. Shifren JL, Braunstein GD, Simon JA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
22. Nathorst-Boos J, Floter A, Jarkander-Rolff M. Treatment with percutaneous testosterone gel in postmenopausal women with decreased libido effects on sexuality and psychological general well-being. Maturitas 2005;53:11-8.
23. Shifren J, Davis SR, Morgeau M. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the Intimate NM1 study. Menopause 2006;13:770-9.
24. Braunstein GD, Sundwall DA, Katz M. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomised, placebo-controlled trial. Arch Intern Med 2005;165:1582-9.
25. Buster JE, Kingsberg SA, Aguirre O. Testosterone patch for low sexual desire in surgically menopausal women: A randomizel trial. Obstet Gynecol 2005;105:944-52.
26. Davis SR, Van der Mooren M, Van Lunsen RH. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal woman: A randomised placebo-controlled trial. Menopause 2006;13:387-96.
27. Simon J, Braunstein G, Machtigall L. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33.
28. Miller KK, Bitter BMK, Beauregard C. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: A randomised double-bind, placebo-controlled study. J Clin Endocrinol Metab 2006;91:1683-90.
29. Arlt W, Callies F, Van Vlijmen. Dehydroeplandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013-20.
30. Johannsson G, Burmann P, Wiren L. Low dose dehydroepiandosterone affects behaviour in hypopituitary androgen-deficient women: A placebo-controlled trial. J Clin Endocrinol Metab 2002;87:2046-52.
31. Hunt PJ, Gurnett EM, Huppert FA. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomised, double blind trial. J Clin Endocrinol Metab 2000;85:4650-6.
32. Beaulieu EE, Thomas G, Legrain S. Dehydroepiandrosterone (DHEA). DHEA sulfate and ageing: A contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-84.
33. Nathorst-Böös J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15-20.
34. Schmidt PJ, Daly RC, Bloch M. Dehydroepindrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiat 2005;62: 154-62.
35. Barnheat KT, Freeman E, Grisso JA. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84:3896-902.
36. Nair KS, Rizza RA, O'Brian P. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1724-6.
37. Melton LJ, Khosia S, Malkasian GF. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003;18:900-5.
38. Antoniucci DM, Sellimeyer DE, Cauley JA. Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women. J Bone Miner Res 2005;20:741-7.
39. Miller BE, De Souha JM, Stade K. Sublingual administration of micronized estradiol and progesterone. with and without micronized testosterone; effect on biochemical markers of bone metabolism and bone mineral density. Menopause 2000;7:318-26.
40. Raisz LG, Wiita B, Artis A. Comparison of the effects on estrogens plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37-43.
41. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 2000;7:395-401.
42. Dobs AS, Nguyen T, Pace C. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002;87:1509-16.
43. Weinberg ME, Manson JE, Buring JE, et al. Low SHBG is associated with the metabolic syndrome in postmenopausal women. Metabolism 2006;55:1473-80.
44. Smith AM, English KM, Malkin CJ. Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol 2005;152:285-91.
45. Brenner RM, Steyden OH, Nayak NR. A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonist steroids. Steroids 2003;68: 1033-9.
46. Hackenberg R, Beck S, Flimer A. Androgen responsiveness of the new human endometrial cancer cell line MEE-296. Int J Cancer 1994;57:117-22.
47. Somoboonporn W, Davis S. Testosterone effects on the breast: Implications for testosterone therapy for women. Endocr Rev 2004;25:374-88.
48. Tamimi RM, Hankinson SE, Chen WY, et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Int Med 2006;166:1483-9.